nodes	percent_of_prediction	percent_of_DWPC	metapath
Mivacurium—BCHE—breast cancer	0.651	1	CbGaD
Mivacurium—CHRM3—muscle of abdomen—breast cancer	0.00926	0.271	CbGeAlD
Mivacurium—CHRNA2—mammary gland—breast cancer	0.00407	0.119	CbGeAlD
Mivacurium—Doxacurium chloride—BCHE—breast cancer	0.00181	1	CrCbGaD
Mivacurium—CHRNA1—endocrine gland—breast cancer	0.00172	0.0503	CbGeAlD
Mivacurium—CHRNB1—adipose tissue—breast cancer	0.00171	0.0499	CbGeAlD
Mivacurium—CHRNB1—adrenal gland—breast cancer	0.00153	0.0448	CbGeAlD
Mivacurium—CHRNB1—female gonad—breast cancer	0.00143	0.0418	CbGeAlD
Mivacurium—CHRNA2—endocrine gland—breast cancer	0.00143	0.0418	CbGeAlD
Mivacurium—BCHE—nipple—breast cancer	0.00134	0.0391	CbGeAlD
Mivacurium—CHRNB1—lymph node—breast cancer	0.000918	0.0269	CbGeAlD
Mivacurium—CHRM3—adipose tissue—breast cancer	0.000891	0.0261	CbGeAlD
Mivacurium—Flushing—Tamoxifen—breast cancer	0.000875	0.00348	CcSEcCtD
Mivacurium—Rash—Lapatinib—breast cancer	0.00087	0.00346	CcSEcCtD
Mivacurium—Dermatitis—Lapatinib—breast cancer	0.000869	0.00346	CcSEcCtD
Mivacurium—Flushing—Melphalan—breast cancer	0.000857	0.00341	CcSEcCtD
Mivacurium—BCHE—skin of body—breast cancer	0.000856	0.025	CbGeAlD
Mivacurium—CHRM2—endocrine gland—breast cancer	0.000851	0.0249	CbGeAlD
Mivacurium—Arrhythmia—Tamoxifen—breast cancer	0.000842	0.00335	CcSEcCtD
Mivacurium—Dizziness—Fulvestrant—breast cancer	0.000839	0.00334	CcSEcCtD
Mivacurium—Cardiac disorder—Goserelin—breast cancer	0.000836	0.00333	CcSEcCtD
Mivacurium—Immune system disorder—Melphalan—breast cancer	0.000834	0.00332	CcSEcCtD
Mivacurium—Mediastinal disorder—Melphalan—breast cancer	0.000832	0.00331	CcSEcCtD
Mivacurium—Dizziness—Toremifene—breast cancer	0.000828	0.0033	CcSEcCtD
Mivacurium—Arrhythmia—Melphalan—breast cancer	0.000825	0.00328	CcSEcCtD
Mivacurium—Erythema—Tamoxifen—breast cancer	0.000821	0.00327	CcSEcCtD
Mivacurium—CHRM3—female reproductive system—breast cancer	0.000819	0.024	CbGeAlD
Mivacurium—Angiopathy—Goserelin—breast cancer	0.000817	0.00325	CcSEcCtD
Mivacurium—Immune system disorder—Goserelin—breast cancer	0.000813	0.00324	CcSEcCtD
Mivacurium—BCHE—endometrium—breast cancer	0.000807	0.0236	CbGeAlD
Mivacurium—Arrhythmia—Goserelin—breast cancer	0.000805	0.0032	CcSEcCtD
Mivacurium—Rash—Fulvestrant—breast cancer	0.0008	0.00318	CcSEcCtD
Mivacurium—Dermatitis—Fulvestrant—breast cancer	0.000799	0.00318	CcSEcCtD
Mivacurium—Bronchospasm—Gemcitabine—breast cancer	0.000796	0.00317	CcSEcCtD
Mivacurium—Rash—Toremifene—breast cancer	0.000789	0.00314	CcSEcCtD
Mivacurium—Muscle spasms—Tamoxifen—breast cancer	0.000789	0.00314	CcSEcCtD
Mivacurium—Dermatitis—Toremifene—breast cancer	0.000789	0.00314	CcSEcCtD
Mivacurium—Erythema—Goserelin—breast cancer	0.000784	0.00312	CcSEcCtD
Mivacurium—Urticaria—Letrozole—breast cancer	0.000778	0.0031	CcSEcCtD
Mivacurium—Urticaria—Anastrozole—breast cancer	0.000778	0.0031	CcSEcCtD
Mivacurium—Phlebitis—Docetaxel—breast cancer	0.000772	0.00307	CcSEcCtD
Mivacurium—Muscle spasms—Goserelin—breast cancer	0.000754	0.003	CcSEcCtD
Mivacurium—Flushing—Vinorelbine—breast cancer	0.000749	0.00298	CcSEcCtD
Mivacurium—Cardiac disorder—Vinorelbine—breast cancer	0.000749	0.00298	CcSEcCtD
Mivacurium—Phlebitis—Capecitabine—breast cancer	0.000747	0.00297	CcSEcCtD
Mivacurium—CHRM3—female gonad—breast cancer	0.000745	0.0218	CbGeAlD
Mivacurium—BCHE—uterus—breast cancer	0.000744	0.0218	CbGeAlD
Mivacurium—Urticaria—Idarubicin—breast cancer	0.000738	0.00294	CcSEcCtD
Mivacurium—Angiopathy—Vinorelbine—breast cancer	0.000732	0.00291	CcSEcCtD
Mivacurium—BCHE—pituitary gland—breast cancer	0.00073	0.0214	CbGeAlD
Mivacurium—Immune system disorder—Vinorelbine—breast cancer	0.000729	0.0029	CcSEcCtD
Mivacurium—Dizziness—Exemestane—breast cancer	0.000729	0.0029	CcSEcCtD
Mivacurium—BCHE—adipose tissue—breast cancer	0.000727	0.0213	CbGeAlD
Mivacurium—Mediastinal disorder—Vinorelbine—breast cancer	0.000727	0.00289	CcSEcCtD
Mivacurium—Arrhythmia—Vinorelbine—breast cancer	0.000721	0.00287	CcSEcCtD
Mivacurium—Cardiac disorder—Thiotepa—breast cancer	0.000715	0.00285	CcSEcCtD
Mivacurium—Erythema—Vinorelbine—breast cancer	0.000702	0.00279	CcSEcCtD
Mivacurium—Angiopathy—Thiotepa—breast cancer	0.000699	0.00278	CcSEcCtD
Mivacurium—Immune system disorder—Thiotepa—breast cancer	0.000696	0.00277	CcSEcCtD
Mivacurium—Rash—Exemestane—breast cancer	0.000695	0.00277	CcSEcCtD
Mivacurium—Mediastinal disorder—Thiotepa—breast cancer	0.000694	0.00276	CcSEcCtD
Mivacurium—Dermatitis—Exemestane—breast cancer	0.000694	0.00276	CcSEcCtD
Mivacurium—CHRM3—endocrine gland—breast cancer	0.000693	0.0203	CbGeAlD
Mivacurium—Arrhythmia—Thiotepa—breast cancer	0.000688	0.00274	CcSEcCtD
Mivacurium—Dizziness—Ixabepilone—breast cancer	0.000687	0.00274	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Melphalan—breast cancer	0.00068	0.0027	CcSEcCtD
Mivacurium—Bradycardia—Irinotecan—breast cancer	0.000677	0.0027	CcSEcCtD
Mivacurium—Bradycardia—Mitoxantrone—breast cancer	0.000677	0.0027	CcSEcCtD
Mivacurium—Erythema—Thiotepa—breast cancer	0.000671	0.00267	CcSEcCtD
Mivacurium—BCHE—female reproductive system—breast cancer	0.000668	0.0196	CbGeAlD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Goserelin—breast cancer	0.000663	0.00264	CcSEcCtD
Mivacurium—Anaphylactic shock—Melphalan—breast cancer	0.000656	0.00261	CcSEcCtD
Mivacurium—Rash—Ixabepilone—breast cancer	0.000655	0.00261	CcSEcCtD
Mivacurium—Dermatitis—Ixabepilone—breast cancer	0.000655	0.00261	CcSEcCtD
Mivacurium—BCHE—adrenal gland—breast cancer	0.000652	0.0191	CbGeAlD
Mivacurium—Dizziness—Letrozole—breast cancer	0.000647	0.00258	CcSEcCtD
Mivacurium—Dizziness—Anastrozole—breast cancer	0.000647	0.00258	CcSEcCtD
Mivacurium—Tachycardia—Melphalan—breast cancer	0.00064	0.00255	CcSEcCtD
Mivacurium—Anaphylactic shock—Goserelin—breast cancer	0.00064	0.00255	CcSEcCtD
Mivacurium—Skin disorder—Melphalan—breast cancer	0.000637	0.00254	CcSEcCtD
Mivacurium—BCHE—bone marrow—breast cancer	0.000631	0.0185	CbGeAlD
Mivacurium—Tachycardia—Goserelin—breast cancer	0.000624	0.00249	CcSEcCtD
Mivacurium—Skin disorder—Goserelin—breast cancer	0.000621	0.00247	CcSEcCtD
Mivacurium—Flushing—Irinotecan—breast cancer	0.000617	0.00246	CcSEcCtD
Mivacurium—Cardiac disorder—Irinotecan—breast cancer	0.000617	0.00246	CcSEcCtD
Mivacurium—Rash—Letrozole—breast cancer	0.000617	0.00246	CcSEcCtD
Mivacurium—Rash—Anastrozole—breast cancer	0.000617	0.00246	CcSEcCtD
Mivacurium—Dermatitis—Anastrozole—breast cancer	0.000617	0.00245	CcSEcCtD
Mivacurium—Dermatitis—Letrozole—breast cancer	0.000617	0.00245	CcSEcCtD
Mivacurium—Dizziness—Raloxifene—breast cancer	0.000614	0.00245	CcSEcCtD
Mivacurium—Injection site reaction—Epirubicin—breast cancer	0.000614	0.00244	CcSEcCtD
Mivacurium—Hypotension—Melphalan—breast cancer	0.000613	0.00244	CcSEcCtD
Mivacurium—Angiopathy—Irinotecan—breast cancer	0.000604	0.0024	CcSEcCtD
Mivacurium—Cardiac disorder—Gemcitabine—breast cancer	0.000601	0.00239	CcSEcCtD
Mivacurium—Immune system disorder—Irinotecan—breast cancer	0.000601	0.00239	CcSEcCtD
Mivacurium—Mediastinal disorder—Irinotecan—breast cancer	0.0006	0.00239	CcSEcCtD
Mivacurium—Hypotension—Goserelin—breast cancer	0.000598	0.00238	CcSEcCtD
Mivacurium—Urticaria—Chlorambucil—breast cancer	0.000598	0.00238	CcSEcCtD
Mivacurium—Arrhythmia—Mitoxantrone—breast cancer	0.000594	0.00237	CcSEcCtD
Mivacurium—Arrhythmia—Irinotecan—breast cancer	0.000594	0.00237	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—breast cancer	0.000594	0.00236	CcSEcCtD
Mivacurium—Angiopathy—Gemcitabine—breast cancer	0.000588	0.00234	CcSEcCtD
Mivacurium—Rash—Raloxifene—breast cancer	0.000586	0.00233	CcSEcCtD
Mivacurium—Rash—Idarubicin—breast cancer	0.000586	0.00233	CcSEcCtD
Mivacurium—Immune system disorder—Gemcitabine—breast cancer	0.000585	0.00233	CcSEcCtD
Mivacurium—Dermatitis—Idarubicin—breast cancer	0.000585	0.00233	CcSEcCtD
Mivacurium—Dermatitis—Raloxifene—breast cancer	0.000585	0.00233	CcSEcCtD
Mivacurium—Mediastinal disorder—Gemcitabine—breast cancer	0.000584	0.00232	CcSEcCtD
Mivacurium—Erythema—Mitoxantrone—breast cancer	0.000579	0.00231	CcSEcCtD
Mivacurium—Arrhythmia—Gemcitabine—breast cancer	0.000579	0.0023	CcSEcCtD
Mivacurium—Anaphylactic shock—Vinorelbine—breast cancer	0.000573	0.00228	CcSEcCtD
Mivacurium—Arrhythmia—Fluorouracil—breast cancer	0.000569	0.00227	CcSEcCtD
Mivacurium—Injection site reaction—Doxorubicin—breast cancer	0.000568	0.00226	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—breast cancer	0.000567	0.00226	CcSEcCtD
Mivacurium—BCHE—endocrine gland—breast cancer	0.000566	0.0166	CbGeAlD
Mivacurium—Bronchospasm—Docetaxel—breast cancer	0.000565	0.00225	CcSEcCtD
Mivacurium—Erythema—Gemcitabine—breast cancer	0.000564	0.00225	CcSEcCtD
Mivacurium—Tachycardia—Vinorelbine—breast cancer	0.000559	0.00223	CcSEcCtD
Mivacurium—Muscle spasms—Irinotecan—breast cancer	0.000557	0.00222	CcSEcCtD
Mivacurium—Skin disorder—Vinorelbine—breast cancer	0.000557	0.00222	CcSEcCtD
Mivacurium—Erythema—Fluorouracil—breast cancer	0.000555	0.00221	CcSEcCtD
Mivacurium—Bradycardia—Paclitaxel—breast cancer	0.000552	0.0022	CcSEcCtD
Mivacurium—Bronchospasm—Capecitabine—breast cancer	0.000547	0.00218	CcSEcCtD
Mivacurium—Hypotension—Vinorelbine—breast cancer	0.000535	0.00213	CcSEcCtD
Mivacurium—Tachycardia—Thiotepa—breast cancer	0.000534	0.00213	CcSEcCtD
Mivacurium—Urticaria—Tamoxifen—breast cancer	0.000532	0.00212	CcSEcCtD
Mivacurium—Skin disorder—Thiotepa—breast cancer	0.000532	0.00212	CcSEcCtD
Mivacurium—Urticaria—Melphalan—breast cancer	0.000521	0.00207	CcSEcCtD
Mivacurium—Phlebitis—Epirubicin—breast cancer	0.00052	0.00207	CcSEcCtD
Mivacurium—Urticaria—Goserelin—breast cancer	0.000508	0.00202	CcSEcCtD
Mivacurium—Flushing—Paclitaxel—breast cancer	0.000504	0.002	CcSEcCtD
Mivacurium—Cardiac disorder—Paclitaxel—breast cancer	0.000504	0.002	CcSEcCtD
Mivacurium—Anaphylactoid reaction—Methotrexate—breast cancer	0.000495	0.00197	CcSEcCtD
Mivacurium—Angiopathy—Paclitaxel—breast cancer	0.000492	0.00196	CcSEcCtD
Mivacurium—Immune system disorder—Paclitaxel—breast cancer	0.00049	0.00195	CcSEcCtD
Mivacurium—Mediastinal disorder—Paclitaxel—breast cancer	0.000489	0.00195	CcSEcCtD
Mivacurium—Arrhythmia—Paclitaxel—breast cancer	0.000485	0.00193	CcSEcCtD
Mivacurium—Phlebitis—Doxorubicin—breast cancer	0.000482	0.00192	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—breast cancer	0.000477	0.0019	CcSEcCtD
Mivacurium—Anaphylactic shock—Irinotecan—breast cancer	0.000473	0.00188	CcSEcCtD
Mivacurium—Anaphylactic shock—Mitoxantrone—breast cancer	0.000473	0.00188	CcSEcCtD
Mivacurium—Erythema—Paclitaxel—breast cancer	0.000472	0.00188	CcSEcCtD
Mivacurium—Anaphylactoid reaction—Epirubicin—breast cancer	0.000463	0.00184	CcSEcCtD
Mivacurium—Tachycardia—Mitoxantrone—breast cancer	0.000461	0.00184	CcSEcCtD
Mivacurium—Anaphylactic shock—Gemcitabine—breast cancer	0.00046	0.00183	CcSEcCtD
Mivacurium—Skin disorder—Mitoxantrone—breast cancer	0.000459	0.00183	CcSEcCtD
Mivacurium—Dizziness—Vinblastine—breast cancer	0.000456	0.00182	CcSEcCtD
Mivacurium—Urticaria—Vinorelbine—breast cancer	0.000455	0.00181	CcSEcCtD
Mivacurium—Muscle spasms—Paclitaxel—breast cancer	0.000454	0.00181	CcSEcCtD
Mivacurium—Bradycardia—Capecitabine—breast cancer	0.000453	0.0018	CcSEcCtD
Mivacurium—Anaphylactic shock—Fluorouracil—breast cancer	0.000453	0.0018	CcSEcCtD
Mivacurium—Skin disorder—Gemcitabine—breast cancer	0.000447	0.00178	CcSEcCtD
Mivacurium—Dizziness—Tamoxifen—breast cancer	0.000443	0.00176	CcSEcCtD
Mivacurium—Tachycardia—Fluorouracil—breast cancer	0.000442	0.00176	CcSEcCtD
Mivacurium—Hypotension—Mitoxantrone—breast cancer	0.000442	0.00176	CcSEcCtD
Mivacurium—Hypotension—Irinotecan—breast cancer	0.000442	0.00176	CcSEcCtD
Mivacurium—Urticaria—Thiotepa—breast cancer	0.000435	0.00173	CcSEcCtD
Mivacurium—Hypotension—Gemcitabine—breast cancer	0.00043	0.00171	CcSEcCtD
Mivacurium—Anaphylactoid reaction—Doxorubicin—breast cancer	0.000429	0.00171	CcSEcCtD
Mivacurium—Flushing—Docetaxel—breast cancer	0.000427	0.0017	CcSEcCtD
Mivacurium—Cardiac disorder—Docetaxel—breast cancer	0.000427	0.0017	CcSEcCtD
Mivacurium—Dizziness—Goserelin—breast cancer	0.000423	0.00168	CcSEcCtD
Mivacurium—Hypotension—Fluorouracil—breast cancer	0.000423	0.00168	CcSEcCtD
Mivacurium—Rash—Tamoxifen—breast cancer	0.000422	0.00168	CcSEcCtD
Mivacurium—Dermatitis—Tamoxifen—breast cancer	0.000422	0.00168	CcSEcCtD
Mivacurium—Angiopathy—Docetaxel—breast cancer	0.000417	0.00166	CcSEcCtD
Mivacurium—Immune system disorder—Docetaxel—breast cancer	0.000415	0.00165	CcSEcCtD
Mivacurium—Mediastinal disorder—Docetaxel—breast cancer	0.000414	0.00165	CcSEcCtD
Mivacurium—Rash—Melphalan—breast cancer	0.000414	0.00165	CcSEcCtD
Mivacurium—Cardiac disorder—Capecitabine—breast cancer	0.000413	0.00164	CcSEcCtD
Mivacurium—Flushing—Capecitabine—breast cancer	0.000413	0.00164	CcSEcCtD
Mivacurium—Dermatitis—Melphalan—breast cancer	0.000413	0.00164	CcSEcCtD
Mivacurium—Arrhythmia—Docetaxel—breast cancer	0.000411	0.00164	CcSEcCtD
Mivacurium—Angiopathy—Capecitabine—breast cancer	0.000404	0.00161	CcSEcCtD
Mivacurium—Rash—Goserelin—breast cancer	0.000403	0.00161	CcSEcCtD
Mivacurium—Dermatitis—Goserelin—breast cancer	0.000403	0.0016	CcSEcCtD
Mivacurium—Immune system disorder—Capecitabine—breast cancer	0.000402	0.0016	CcSEcCtD
Mivacurium—Mediastinal disorder—Capecitabine—breast cancer	0.000401	0.0016	CcSEcCtD
Mivacurium—Erythema—Docetaxel—breast cancer	0.0004	0.00159	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—breast cancer	0.000399	0.00159	CcSEcCtD
Mivacurium—Arrhythmia—Capecitabine—breast cancer	0.000398	0.00158	CcSEcCtD
Mivacurium—BCHE—lymph node—breast cancer	0.000391	0.0114	CbGeAlD
Mivacurium—Erythema—Capecitabine—breast cancer	0.000388	0.00154	CcSEcCtD
Mivacurium—Anaphylactic shock—Paclitaxel—breast cancer	0.000385	0.00153	CcSEcCtD
Mivacurium—Muscle spasms—Docetaxel—breast cancer	0.000385	0.00153	CcSEcCtD
Mivacurium—Dizziness—Vinorelbine—breast cancer	0.000379	0.00151	CcSEcCtD
Mivacurium—Tachycardia—Paclitaxel—breast cancer	0.000376	0.0015	CcSEcCtD
Mivacurium—Urticaria—Mitoxantrone—breast cancer	0.000375	0.00149	CcSEcCtD
Mivacurium—Skin disorder—Paclitaxel—breast cancer	0.000374	0.00149	CcSEcCtD
Mivacurium—Muscle spasms—Capecitabine—breast cancer	0.000373	0.00148	CcSEcCtD
Mivacurium—Dizziness—Thiotepa—breast cancer	0.000362	0.00144	CcSEcCtD
Mivacurium—Rash—Vinorelbine—breast cancer	0.000361	0.00144	CcSEcCtD
Mivacurium—Dermatitis—Vinorelbine—breast cancer	0.000361	0.00144	CcSEcCtD
Mivacurium—Hypotension—Paclitaxel—breast cancer	0.00036	0.00143	CcSEcCtD
Mivacurium—Urticaria—Fluorouracil—breast cancer	0.00036	0.00143	CcSEcCtD
Mivacurium—Rash—Thiotepa—breast cancer	0.000345	0.00137	CcSEcCtD
Mivacurium—Dermatitis—Thiotepa—breast cancer	0.000345	0.00137	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	0.000338	0.00135	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	0.000328	0.0013	CcSEcCtD
Mivacurium—Anaphylactic shock—Docetaxel—breast cancer	0.000327	0.0013	CcSEcCtD
Mivacurium—Tachycardia—Docetaxel—breast cancer	0.000319	0.00127	CcSEcCtD
Mivacurium—Skin disorder—Docetaxel—breast cancer	0.000317	0.00126	CcSEcCtD
Mivacurium—Bradycardia—Epirubicin—breast cancer	0.000316	0.00126	CcSEcCtD
Mivacurium—Dizziness—Irinotecan—breast cancer	0.000313	0.00124	CcSEcCtD
Mivacurium—Tachycardia—Capecitabine—breast cancer	0.000309	0.00123	CcSEcCtD
Mivacurium—Cardiac disorder—Methotrexate—breast cancer	0.000308	0.00122	CcSEcCtD
Mivacurium—Skin disorder—Capecitabine—breast cancer	0.000307	0.00122	CcSEcCtD
Mivacurium—Urticaria—Paclitaxel—breast cancer	0.000306	0.00122	CcSEcCtD
Mivacurium—Hypotension—Docetaxel—breast cancer	0.000305	0.00122	CcSEcCtD
Mivacurium—Angiopathy—Methotrexate—breast cancer	0.000301	0.0012	CcSEcCtD
Mivacurium—Immune system disorder—Methotrexate—breast cancer	0.000299	0.00119	CcSEcCtD
Mivacurium—Dizziness—Fluorouracil—breast cancer	0.000299	0.00119	CcSEcCtD
Mivacurium—Mediastinal disorder—Methotrexate—breast cancer	0.000299	0.00119	CcSEcCtD
Mivacurium—Rash—Mitoxantrone—breast cancer	0.000298	0.00119	CcSEcCtD
Mivacurium—Rash—Irinotecan—breast cancer	0.000298	0.00119	CcSEcCtD
Mivacurium—Dermatitis—Irinotecan—breast cancer	0.000298	0.00119	CcSEcCtD
Mivacurium—Dermatitis—Mitoxantrone—breast cancer	0.000298	0.00119	CcSEcCtD
Mivacurium—Hypotension—Capecitabine—breast cancer	0.000296	0.00118	CcSEcCtD
Mivacurium—Bradycardia—Doxorubicin—breast cancer	0.000292	0.00116	CcSEcCtD
Mivacurium—Rash—Gemcitabine—breast cancer	0.00029	0.00116	CcSEcCtD
Mivacurium—Dermatitis—Gemcitabine—breast cancer	0.00029	0.00115	CcSEcCtD
Mivacurium—Erythema—Methotrexate—breast cancer	0.000289	0.00115	CcSEcCtD
Mivacurium—Flushing—Epirubicin—breast cancer	0.000288	0.00115	CcSEcCtD
Mivacurium—Cardiac disorder—Epirubicin—breast cancer	0.000288	0.00115	CcSEcCtD
Mivacurium—Rash—Fluorouracil—breast cancer	0.000285	0.00114	CcSEcCtD
Mivacurium—Dermatitis—Fluorouracil—breast cancer	0.000285	0.00114	CcSEcCtD
Mivacurium—Angiopathy—Epirubicin—breast cancer	0.000281	0.00112	CcSEcCtD
Mivacurium—Immune system disorder—Epirubicin—breast cancer	0.00028	0.00112	CcSEcCtD
Mivacurium—Mediastinal disorder—Epirubicin—breast cancer	0.00028	0.00111	CcSEcCtD
Mivacurium—Arrhythmia—Epirubicin—breast cancer	0.000277	0.0011	CcSEcCtD
Mivacurium—Erythema—Epirubicin—breast cancer	0.00027	0.00107	CcSEcCtD
Mivacurium—Flushing—Doxorubicin—breast cancer	0.000266	0.00106	CcSEcCtD
Mivacurium—Cardiac disorder—Doxorubicin—breast cancer	0.000266	0.00106	CcSEcCtD
Mivacurium—Angiopathy—Doxorubicin—breast cancer	0.00026	0.00104	CcSEcCtD
Mivacurium—Muscle spasms—Epirubicin—breast cancer	0.00026	0.00103	CcSEcCtD
Mivacurium—Immune system disorder—Doxorubicin—breast cancer	0.000259	0.00103	CcSEcCtD
Mivacurium—Mediastinal disorder—Doxorubicin—breast cancer	0.000259	0.00103	CcSEcCtD
Mivacurium—Arrhythmia—Doxorubicin—breast cancer	0.000256	0.00102	CcSEcCtD
Mivacurium—Dizziness—Paclitaxel—breast cancer	0.000255	0.00101	CcSEcCtD
Mivacurium—Urticaria—Capecitabine—breast cancer	0.000251	0.001	CcSEcCtD
Mivacurium—Erythema—Doxorubicin—breast cancer	0.00025	0.000994	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	0.000244	0.000971	CcSEcCtD
Mivacurium—Rash—Paclitaxel—breast cancer	0.000243	0.000967	CcSEcCtD
Mivacurium—Dermatitis—Paclitaxel—breast cancer	0.000243	0.000966	CcSEcCtD
Mivacurium—Muscle spasms—Doxorubicin—breast cancer	0.00024	0.000956	CcSEcCtD
Mivacurium—Anaphylactic shock—Methotrexate—breast cancer	0.000235	0.000937	CcSEcCtD
Mivacurium—Skin disorder—Methotrexate—breast cancer	0.000229	0.00091	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	0.000228	0.000909	CcSEcCtD
Mivacurium—Anaphylactic shock—Epirubicin—breast cancer	0.00022	0.000877	CcSEcCtD
Mivacurium—Hypotension—Methotrexate—breast cancer	0.00022	0.000876	CcSEcCtD
Mivacurium—Dizziness—Docetaxel—breast cancer	0.000216	0.00086	CcSEcCtD
Mivacurium—Tachycardia—Epirubicin—breast cancer	0.000215	0.000856	CcSEcCtD
Mivacurium—Skin disorder—Epirubicin—breast cancer	0.000214	0.000852	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	0.000211	0.000841	CcSEcCtD
Mivacurium—Dizziness—Capecitabine—breast cancer	0.000209	0.000833	CcSEcCtD
Mivacurium—Rash—Docetaxel—breast cancer	0.000206	0.00082	CcSEcCtD
Mivacurium—Hypotension—Epirubicin—breast cancer	0.000206	0.00082	CcSEcCtD
Mivacurium—Dermatitis—Docetaxel—breast cancer	0.000206	0.000819	CcSEcCtD
Mivacurium—Anaphylactic shock—Doxorubicin—breast cancer	0.000204	0.000812	CcSEcCtD
Mivacurium—Rash—Capecitabine—breast cancer	0.000199	0.000794	CcSEcCtD
Mivacurium—Dermatitis—Capecitabine—breast cancer	0.000199	0.000793	CcSEcCtD
Mivacurium—Tachycardia—Doxorubicin—breast cancer	0.000199	0.000792	CcSEcCtD
Mivacurium—Skin disorder—Doxorubicin—breast cancer	0.000198	0.000788	CcSEcCtD
Mivacurium—Hypotension—Doxorubicin—breast cancer	0.000191	0.000758	CcSEcCtD
Mivacurium—Urticaria—Methotrexate—breast cancer	0.000187	0.000745	CcSEcCtD
Mivacurium—Urticaria—Epirubicin—breast cancer	0.000175	0.000697	CcSEcCtD
Mivacurium—Urticaria—Doxorubicin—breast cancer	0.000162	0.000645	CcSEcCtD
Mivacurium—Dizziness—Methotrexate—breast cancer	0.000156	0.00062	CcSEcCtD
Mivacurium—Rash—Methotrexate—breast cancer	0.000148	0.000591	CcSEcCtD
Mivacurium—Dermatitis—Methotrexate—breast cancer	0.000148	0.00059	CcSEcCtD
Mivacurium—Dizziness—Epirubicin—breast cancer	0.000146	0.00058	CcSEcCtD
Mivacurium—Rash—Epirubicin—breast cancer	0.000139	0.000553	CcSEcCtD
Mivacurium—Dermatitis—Epirubicin—breast cancer	0.000139	0.000553	CcSEcCtD
Mivacurium—Dizziness—Doxorubicin—breast cancer	0.000135	0.000537	CcSEcCtD
Mivacurium—Rash—Doxorubicin—breast cancer	0.000129	0.000512	CcSEcCtD
Mivacurium—Dermatitis—Doxorubicin—breast cancer	0.000128	0.000511	CcSEcCtD
Mivacurium—CHRM2—GPCR downstream signaling—PIK3CG—breast cancer	1.27e-05	0.000206	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—NOTCH3—breast cancer	1.27e-05	0.000206	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PARP1—breast cancer	1.27e-05	0.000206	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—JAG1—breast cancer	1.26e-05	0.000205	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PARP1—breast cancer	1.26e-05	0.000204	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—NOTCH3—breast cancer	1.26e-05	0.000204	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CALCA—breast cancer	1.26e-05	0.000203	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CALCA—breast cancer	1.24e-05	0.000201	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—RPS6—breast cancer	1.24e-05	0.000201	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—FGF4—breast cancer	1.23e-05	0.000199	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—RPS6—breast cancer	1.23e-05	0.000199	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CXCR4—breast cancer	1.23e-05	0.000199	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CXCL12—breast cancer	1.23e-05	0.000199	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—FGF4—breast cancer	1.22e-05	0.000197	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—COMT—breast cancer	1.21e-05	0.000197	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CXCL12—breast cancer	1.21e-05	0.000197	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CXCR4—breast cancer	1.21e-05	0.000197	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—GSTP1—breast cancer	1.21e-05	0.000196	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PAK1—breast cancer	1.2e-05	0.000195	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—HMOX1—breast cancer	1.19e-05	0.000193	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PAK1—breast cancer	1.19e-05	0.000193	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ITPR1—breast cancer	1.19e-05	0.000193	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—TCF7L2—breast cancer	1.18e-05	0.000192	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—CAV1—breast cancer	1.18e-05	0.000191	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—AKT2—breast cancer	1.18e-05	0.000191	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—TCF7L2—breast cancer	1.17e-05	0.00019	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—PIK3CG—breast cancer	1.17e-05	0.000189	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—AKT2—breast cancer	1.17e-05	0.000189	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—PIK3CG—breast cancer	1.16e-05	0.000187	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ABCB1—breast cancer	1.14e-05	0.000185	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HSP90AA1—breast cancer	1.14e-05	0.000185	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—NOTCH2—breast cancer	1.14e-05	0.000185	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—PIK3CD—breast cancer	1.13e-05	0.000183	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—NOTCH2—breast cancer	1.13e-05	0.000183	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HSP90AA1—breast cancer	1.13e-05	0.000183	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.13e-05	0.000182	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—TYMS—breast cancer	1.12e-05	0.000182	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—PIK3CD—breast cancer	1.12e-05	0.000181	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PLA2G4A—breast cancer	1.11e-05	0.00018	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—NCOR1—breast cancer	1.11e-05	0.00018	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—GSTM1—breast cancer	1.11e-05	0.00018	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PRL—breast cancer	1.11e-05	0.00018	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—AGTR1—breast cancer	1.11e-05	0.00018	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—AGTR1—breast cancer	1.1e-05	0.000178	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PRL—breast cancer	1.1e-05	0.000178	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—STK11—breast cancer	1.09e-05	0.000177	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ADAM10—breast cancer	1.09e-05	0.000177	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ADAM10—breast cancer	1.08e-05	0.000175	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—STK11—breast cancer	1.08e-05	0.000175	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PLG—breast cancer	1.08e-05	0.000175	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PIK3CG—breast cancer	1.07e-05	0.000174	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PLG—breast cancer	1.07e-05	0.000173	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—AKT2—breast cancer	1.07e-05	0.000173	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—GPX1—breast cancer	1.06e-05	0.000172	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—FGF10—breast cancer	1.06e-05	0.000172	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—AKT2—breast cancer	1.06e-05	0.000171	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CYP1A1—breast cancer	1.05e-05	0.000171	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—FGF10—breast cancer	1.05e-05	0.000171	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ERCC2—breast cancer	1.04e-05	0.000169	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—PIK3CD—breast cancer	1.03e-05	0.000166	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PDGFA—breast cancer	1.03e-05	0.000166	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—PIK3CD—breast cancer	1.02e-05	0.000165	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PDGFA—breast cancer	1.02e-05	0.000165	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—TGFBR2—breast cancer	1.01e-05	0.000164	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—TGFBR2—breast cancer	1e-05	0.000162	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ITPR1—breast cancer	9.95e-06	0.000161	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ERBB4—breast cancer	9.88e-06	0.00016	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—STAT5A—breast cancer	9.88e-06	0.00016	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MMP3—breast cancer	9.88e-06	0.00016	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—PIK3CB—breast cancer	9.86e-06	0.00016	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ITPR1—breast cancer	9.85e-06	0.00016	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—MTHFR—breast cancer	9.82e-06	0.000159	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ERBB4—breast cancer	9.79e-06	0.000159	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MMP3—breast cancer	9.79e-06	0.000159	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—STAT5A—breast cancer	9.79e-06	0.000159	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—PIK3CB—breast cancer	9.76e-06	0.000158	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—SMAD4—breast cancer	9.57e-06	0.000155	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—IGF1R—breast cancer	9.51e-06	0.000154	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—SMAD4—breast cancer	9.48e-06	0.000154	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—CXCL8—breast cancer	9.47e-06	0.000153	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PIK3CD—breast cancer	9.43e-06	0.000153	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—IGF1R—breast cancer	9.42e-06	0.000153	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—CXCL8—breast cancer	9.38e-06	0.000152	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HES1—breast cancer	9.35e-06	0.000151	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—ALB—breast cancer	9.31e-06	0.000151	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—NCOR1—breast cancer	9.29e-06	0.000151	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PLA2G4A—breast cancer	9.29e-06	0.000151	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HES1—breast cancer	9.25e-06	0.00015	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—NCOR1—breast cancer	9.2e-06	0.000149	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PLA2G4A—breast cancer	9.2e-06	0.000149	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—FGF1—breast cancer	9.19e-06	0.000149	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CSF2—breast cancer	9.19e-06	0.000149	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—RAF1—breast cancer	9.17e-06	0.000148	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—NRG1—breast cancer	9.12e-06	0.000148	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CSF2—breast cancer	9.1e-06	0.000147	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—FGF1—breast cancer	9.1e-06	0.000147	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—RAF1—breast cancer	9.08e-06	0.000147	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CAV1—breast cancer	9.06e-06	0.000147	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—H2AFX—breast cancer	9.06e-06	0.000147	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—IL2—breast cancer	9.05e-06	0.000147	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—NRG1—breast cancer	9.03e-06	0.000146	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—E2F1—breast cancer	8.99e-06	0.000146	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—H2AFX—breast cancer	8.97e-06	0.000145	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—IL2—breast cancer	8.96e-06	0.000145	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—PIK3CB—breast cancer	8.95e-06	0.000145	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—NOS3—breast cancer	8.91e-06	0.000144	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—E2F1—breast cancer	8.9e-06	0.000144	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—PIK3CB—breast cancer	8.86e-06	0.000144	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—SPP1—breast cancer	8.64e-06	0.00014	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—CXCL8—breast cancer	8.6e-06	0.000139	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—SPP1—breast cancer	8.55e-06	0.000139	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ERBB3—breast cancer	8.54e-06	0.000138	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—FGFR2—breast cancer	8.53e-06	0.000138	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—CXCL8—breast cancer	8.52e-06	0.000138	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ERBB3—breast cancer	8.46e-06	0.000137	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—FGFR2—breast cancer	8.45e-06	0.000137	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PIK3CG—breast cancer	8.25e-06	0.000134	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PIK3CB—breast cancer	8.22e-06	0.000133	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—IL2—breast cancer	8.22e-06	0.000133	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—TERT—breast cancer	8.19e-06	0.000133	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PTGS2—breast cancer	8.15e-06	0.000132	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—IL2—breast cancer	8.14e-06	0.000132	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—TERT—breast cancer	8.11e-06	0.000131	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—FGFR1—breast cancer	7.95e-06	0.000129	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—FGFR1—breast cancer	7.87e-06	0.000128	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HIF1A—breast cancer	7.83e-06	0.000127	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HIF1A—breast cancer	7.76e-06	0.000126	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—LEP—breast cancer	7.65e-06	0.000124	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CAV1—breast cancer	7.57e-06	0.000123	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—LEP—breast cancer	7.57e-06	0.000123	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CAV1—breast cancer	7.5e-06	0.000122	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—KDR—breast cancer	7.49e-06	0.000121	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—KDR—breast cancer	7.42e-06	0.00012	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ESR1—breast cancer	7.3e-06	0.000118	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PIK3CD—breast cancer	7.25e-06	0.000118	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ESR1—breast cancer	7.23e-06	0.000117	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—FN1—breast cancer	7.21e-06	0.000117	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ALB—breast cancer	7.16e-06	0.000116	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—FN1—breast cancer	7.14e-06	0.000116	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—NFKBIA—breast cancer	7.12e-06	0.000115	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PTEN—breast cancer	7.11e-06	0.000115	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—NOTCH1—breast cancer	7.06e-06	0.000114	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—NFKBIA—breast cancer	7.05e-06	0.000114	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—NOTCH1—breast cancer	6.99e-06	0.000113	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—APC—breast cancer	6.9e-06	0.000112	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PIK3CG—breast cancer	6.9e-06	0.000112	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—KIT—breast cancer	6.9e-06	0.000112	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—NOS3—breast cancer	6.85e-06	0.000111	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—APC—breast cancer	6.83e-06	0.000111	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—KIT—breast cancer	6.83e-06	0.000111	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PIK3CG—breast cancer	6.83e-06	0.000111	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—EGF—breast cancer	6.82e-06	0.00011	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—EGF—breast cancer	6.75e-06	0.000109	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—MAPK3—breast cancer	6.61e-06	0.000107	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—MAPK3—breast cancer	6.54e-06	0.000106	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—BRAF—breast cancer	6.49e-06	0.000105	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—BRAF—breast cancer	6.42e-06	0.000104	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PIK3CB—breast cancer	6.32e-06	0.000102	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—IGF1—breast cancer	6.32e-06	0.000102	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—AKT2—breast cancer	6.31e-06	0.000102	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—EGFR—breast cancer	6.29e-06	0.000102	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PTGS2—breast cancer	6.26e-06	0.000101	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—IGF1—breast cancer	6.26e-06	0.000101	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—AKT2—breast cancer	6.25e-06	0.000101	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—EGFR—breast cancer	6.22e-06	0.000101	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PIK3CD—breast cancer	6.07e-06	9.83e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—PIK3CA—breast cancer	6.01e-06	9.73e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PIK3CD—breast cancer	6.01e-06	9.73e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—SERPINE1—breast cancer	6e-06	9.72e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—PIK3CA—breast cancer	5.95e-06	9.64e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—SERPINE1—breast cancer	5.94e-06	9.62e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—KRAS—breast cancer	5.94e-06	9.62e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—KRAS—breast cancer	5.88e-06	9.53e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—NOS3—breast cancer	5.73e-06	9.28e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—NOS3—breast cancer	5.67e-06	9.19e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PTEN—breast cancer	5.46e-06	8.85e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—PIK3CA—breast cancer	5.46e-06	8.84e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MDM2—breast cancer	5.43e-06	8.8e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—RAF1—breast cancer	5.42e-06	8.77e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—PIK3CA—breast cancer	5.4e-06	8.75e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—RELA—breast cancer	5.39e-06	8.73e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MDM2—breast cancer	5.38e-06	8.72e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—RAF1—breast cancer	5.36e-06	8.69e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ERBB2—breast cancer	5.36e-06	8.68e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—RELA—breast cancer	5.34e-06	8.65e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ERBB2—breast cancer	5.31e-06	8.59e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MTOR—breast cancer	5.29e-06	8.56e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PIK3CB—breast cancer	5.29e-06	8.56e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PIK3CB—breast cancer	5.24e-06	8.48e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MTOR—breast cancer	5.24e-06	8.48e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CXCL8—breast cancer	5.08e-06	8.23e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—HRAS—breast cancer	5.05e-06	8.18e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CXCL8—breast cancer	5.03e-06	8.15e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PIK3CA—breast cancer	5.01e-06	8.12e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—HRAS—breast cancer	5e-06	8.1e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CDKN1B—breast cancer	4.96e-06	8.04e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CDKN1B—breast cancer	4.91e-06	7.96e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—AKT1—breast cancer	4.91e-06	7.95e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CASP3—breast cancer	4.86e-06	7.88e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—AKT1—breast cancer	4.86e-06	7.87e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—IL2—breast cancer	4.86e-06	7.87e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—IL6—breast cancer	4.83e-06	7.83e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CASP3—breast cancer	4.82e-06	7.8e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—IL2—breast cancer	4.81e-06	7.79e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—IL6—breast cancer	4.78e-06	7.75e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CCND1—breast cancer	4.73e-06	7.67e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—JUN—breast cancer	4.72e-06	7.65e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CCND1—breast cancer	4.69e-06	7.59e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CTNNB1—breast cancer	4.69e-06	7.59e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—JUN—breast cancer	4.68e-06	7.58e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CTNNB1—breast cancer	4.64e-06	7.52e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MMP9—breast cancer	4.6e-06	7.44e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CDKN1A—breast cancer	4.58e-06	7.42e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PTEN—breast cancer	4.57e-06	7.4e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MMP9—breast cancer	4.55e-06	7.37e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CDKN1A—breast cancer	4.53e-06	7.35e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PTEN—breast cancer	4.52e-06	7.33e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MAPK8—breast cancer	4.47e-06	7.24e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—AKT1—breast cancer	4.46e-06	7.22e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MAPK8—breast cancer	4.43e-06	7.17e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—AKT1—breast cancer	4.41e-06	7.15e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—SRC—breast cancer	4.24e-06	6.86e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—SRC—breast cancer	4.2e-06	6.8e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—VEGFA—breast cancer	4.13e-06	6.68e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—AKT1—breast cancer	4.09e-06	6.63e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—VEGFA—breast cancer	4.09e-06	6.62e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—STAT3—breast cancer	4.09e-06	6.62e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—STAT3—breast cancer	4.05e-06	6.55e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MAPK3—breast cancer	3.9e-06	6.32e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MAPK3—breast cancer	3.87e-06	6.26e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PIK3CA—breast cancer	3.85e-06	6.24e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MYC—breast cancer	3.8e-06	6.15e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—TGFB1—breast cancer	3.79e-06	6.14e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MYC—breast cancer	3.76e-06	6.09e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—TGFB1—breast cancer	3.75e-06	6.08e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—EGFR—breast cancer	3.71e-06	6.02e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—EGFR—breast cancer	3.68e-06	5.96e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—KRAS—breast cancer	3.51e-06	5.68e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—KRAS—breast cancer	3.47e-06	5.63e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PIK3CA—breast cancer	3.22e-06	5.22e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PIK3CA—breast cancer	3.19e-06	5.17e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—AKT1—breast cancer	3.15e-06	5.1e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—TP53—breast cancer	3.12e-06	5.05e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—TP53—breast cancer	3.09e-06	5e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HRAS—breast cancer	2.98e-06	4.83e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HRAS—breast cancer	2.95e-06	4.78e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—IL6—breast cancer	2.85e-06	4.62e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—IL6—breast cancer	2.83e-06	4.58e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—AKT1—breast cancer	2.63e-06	4.27e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—AKT1—breast cancer	2.61e-06	4.22e-05	CbGpPWpGaD
